Status:
UNKNOWN
Natural Killer Cells Functions, Tumoral Escape to Immune System and Regulation of Natural Cytotoxixity Receptors in Haematological Malignancies
Lead Sponsor:
Assistance Publique Hopitaux De Marseille
Conditions:
Leukemia
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The NK cells participate in the innate immunity against infectious agents or transformed cells that are recognized as "no self" by the absent, weak or abnormal expression of human leukocyte antigen (H...
Eligibility Criteria
Inclusion
- Grown-up patients having a leukaemia aigue myéloïde (LAM) in the diagnosis, whatever is LAM's subcategory (FAB or cytogenetics).
- The patients that must be informed at the same time, willing, and having given their agreement in writing.
Exclusion
- Refusal of the patient.
- Phénotypage NK not corresponding to the quotas dull / bright required.
Key Trial Info
Start Date :
February 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2015
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT01915992
Start Date
February 1 2013
End Date
January 1 2015
Last Update
September 1 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Assistance Publique Hopitaux de Marseille
Marseille, France, 13354